Haemonetics Corp (NYSE: HAE) is 1.19% higher on its value in year-to-date trading and has touched a low of $70.25 and a high of $97.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HAE stock was last observed hovering at around $78.16 in the last trading session, with the day’s gains setting it 8.37%.
Currently trading at $86.53, the stock is 15.08% and 14.39% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.55 million and changing 10.71% at the moment leaves the stock 6.23% off its SMA200. HAE registered -2.30% loss for a year compared to 6-month loss of -6.56%. The firm has a 50-day simple moving average (SMA 50) of $75.4168 and a 200-day simple moving average (SMA200) of $81.4317.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 13.69% gain in the last 1 month and extending the period to 3 months gives it a 12.33%, and is 21.60% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.36% over the week and 2.65% over the month.
Haemonetics Corp (HAE) has around 3657 employees, a market worth around $4.43B and $1.33B in sales. Current P/E ratio is 38.76 and Fwd P/E is 16.06. Profit margin for the company is 8.61%. Distance from 52-week low is 23.17% and -11.68% from its 52-week high. The company has generated returns on investments over the last 12 months (5.41%).
The EPS is expected to grow by 15.91% this year
435.0 institutions hold shares in Haemonetics Corp (HAE), with institutional investors hold 113.38% of the company’s shares. The shares outstanding are 50.79M, and float is at 50.61M with Short Float at 10.40%. Institutions hold 112.39% of the Float.
The top institutional shareholder in the company is CAPITAL RESEARCH GLOBAL INVESTORS with over 6.92 million shares valued at $572.1 million. The investor’s holdings represent 13.6161 of the HAE Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.96 million shares valued at $493.0 million to account for 11.7335 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.14 million shares representing 10.1221 and valued at over $425.29 million, while WELLINGTON MANAGEMENT GROUP LLP holds 7.5568 of the shares totaling 3.84 million with a market value of $317.51 million.
Haemonetics Corp (HAE) Insider Activity
The most recent transaction is an insider sale by Strong Stewart W, the company’s President, Global Hospital. SEC filings show that Strong Stewart W sold 4,312 shares of the company’s common stock on Jul 26 ’24 at a price of $91.15 per share for a total of $0.39 million. Following the sale, the insider now owns 18196.0 shares.
Still, SEC filings show that on Jul 11 ’24, Lingamneni Anila (EVP, Chief Technology Officer) disposed off 2,136 shares at an average price of $90.00 for $0.19 million. The insider now directly holds 21,410 shares of Haemonetics Corp (HAE).
